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Abstract
Background
Childhood obesity represents a major health concern worldwide due to its well established
detrimental effect on cardiovascular and its potential negative effect on kidney functions.
However, biomarkers that can help diagnose early stages of kidney damage in obese chil-
dren represent an unmet clinical need.
Objectives
In this study, we asked whether the prevalence of microalbuminuria, estimated glomerular
filtration rate (eGFR) or hyperuricemia recorded in a wide cohort of obese children and ado-
lescents would positively correlate with cardiometabolic dysfunction in these subjects.
Methods
We carried out a cross-sectional study on 360 obese children and adolescents between the
ages of 3–18 years, enrolled in a tertiary care center. Clinical and biochemical evaluations
including oral glucose tolerance tests (OGTTs) were performed on all patients. Microalbumi-
nuria was defined as urinary albumin-to-creatinine ratio (u-ACR) of 30–300 mg/g. All data
are expressed as mean ± standard deviation (SD), absolute values or percentages. Sex
age-specific and eGFR SDs were used for statistical analyses. Serum uric acid 5.5 mg/dL
was considered abnormal.
Results
The prevalence of microalbuminuria was 6.4%. Except for a lower insulinogenic-index, no
correlations between microalbuminuria and cardiometabolic risk factors were detected.
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eGFR was < -1 SD and > 1 SD in 1.4% and 60.8% of subjects, respectively. Subjects with
an eGFR > 1 SD had higher systolic blood pressure, liver enzymes, insulin resistance, glu-
cose and insulin during OGTT, lower insulin sensitivity and a more prevalent microalbumi-
nuria. Hyperuricemia (27.5%) increased the odds of hypertension, HDL 10th percentile
and glucose 155.0 mg/dL after 60 minutes of OGTT.
Conclusions
A worse cardiometabolic profile was observed in subjects with an eGFR > 1 SD compared
to other subgroups. Therefore, pediatric obese patients with eGFR > 1 SD or hyperuricemia
should be closely monitored for microalbuminuria and post-challenge glucose and insulin
secretion, all potential indicators of renal dysfunction in these young patients.
Introduction
The rising prevalence of pediatric obesity is one of the most challenging public health issues
worldwide. Most of the major concerns derive from the fact that childhood obesity, besides
increasing traditional cardiometabolic risk factors, can seriously hamper kidney function [1].
In this regard, the recent global obesity epidemic has coincided with a dramatic rise in the
prevalence of end-stage renal disease (ESRD) [1]. To make matters worse, emerging evidence
suggests that renal dysfunction may start early during childhood, long before a diagnosis
of hypertension with type 2 diabetes can be made, and it might be related to pediatric obesity
[1].
Since onset of the obesity-associated renal disease is generally subtle and asymptomatic,
there is clearly an urgent need of biomarkers that could allow early detection of kidney dys-
function in obese children. In this regard, mounting evidence indicates that in adults the prev-
alence of microalbuminuria, which is often associated with nephropathy and atherosclerosis,
positively correlates with the degree of obesity [2,3]. Furthermore, a relationship between
microalbuminuria and obesity has also been reported in children and adolescents [1], although
long-term studies in these patients have yet to be conducted. Interestingly, the association
between estimated glomerular filtration rate (eGFR) and some cardiometabolic risk factors
appears non-linear as either low- or high-normal eGFR has been associated with increased
risk of metabolic diseases and mortality [2]. However, whether eGFR represents a bona fide
cardiometabolic risk indicator, especially in pediatric patients, still remains to be determined
[2,4].
In addition to microalbuminuria, hyperuricemia is another well-established risk factor
for chronic kidney disease (CDK) in adults [5]. This is probably due to the detrimental
effects exerted by uric acid once it permeates a cell, which obviously counteracts its antioxi-
dant activity in the extracellular environment [6]. Therefore, hyperuricemia has a negative
impact on both metabolism and longevity independent of traditional cardiometabolic risk fac-
tors [5]. However, data concerning hyperuricemia in obese children and adolescents are still
lacking.
Here, we have conducted a cross-sectional study on a wide cohort of obese pediatric
patients to determine 1) the prevalence of microalbuminuria; 2) the distribution of age- and
sex-specific eGFRs; 3) the prevalence of hyperuricemia; and 4) any correlations between
microalbuminuria, eGFR and uric acid and other known cardiometabolic markers.
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Abbreviations: AST, Aspartate aminotransferase;
ALT, Alanine aminotransferase; AUC, Area under
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pressure; CDK, Chronic kidney disease; DI,
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filtration rate; ESRD, End-stage renal disease; HDL,
High density lipoprotein cholesterol; (HOMA)-IR,
Homeostasis model assessment–insulin
resistance; IOTF, International Obesity Task Force;
InsI, Insulinogenic index; ISI, Matsuda index; LDL,
Low-density lipoprotein -cholesterol; LMS, Least
median squares method; NHANES, National Health
and Nutrition Examination Survey; OR, Odds ratio;
OGTTs, Oral glucose tolerance tests; QUICKI,
Quantitative Insulin-Sensitivity Check Index; SBP,
Systolic blood pressure; SD, Standard deviation; u-
ACR, Urinary albumin-to-creatinine ratio; WC,
Waist circumference.
Materials and methods
Study design
This was a cross-sectional study. Study quality was assessed (S1 Table). We consecutively
recruited Caucasian children and adolescents, aged 3–18 years, referred to our Pediatric Endo-
crine Service from January 2011 to June 2014 for simple obesity. Subjects were eligible if gener-
ally healthy, overweight or obese, according to the IOTF criteria [7], and naïve to a weight-loss
diet. Among children that had been previously subject to biochemical investigations due to
any medical condition, only healthy children were included in the study. Subjects who refused
to perform an oral glucose tolerance test (OGTT) were included only if they underwent fasting
biochemical evaluations. Exclusion criteria were diagnosed or suspected endocrine or genetic
obesity, type 1 diabetes and previous kidney diseases. Subjects referred to our Service for
known comorbidities of obesity (e.g. glucose alterations, arterial hypertension, dyslipidemia,
liver steatosis, hyperuricemia etc.) were also excluded to avoid interferences due to previous
lifestyle or pharmacological interventions.
The protocol was conducted in accordance with the declaration of Helsinki and was
approved by the Local Ethic Committee of AOU Maggiore della Carità of Novara (CE 95/12).
Informed consents was administered to all patients and parents of minors prior to the evalua-
tions, and the study was carefully explained by the research team to all parents and children.
Only those patients who provided a written informed consent were included in the study.
Anthropometric and biochemical measurements
Height was measured to the nearest 0.1 cm using a Harpenden stadiometer. Body weight was
measured with light clothing to the nearest 0.1 kg using a mechanical column weighing scale
(Wunder, weighing capacity 200 Kg). Body mass index (BMI) was calculated as body weight
divided by squared height (kg/m2). The BMI standard deviation score (BMI-SDS) was calcu-
lated by the least median squares (LMS) method as previously described [8]. Waist circumfer-
ence (WC) was measured at the high point of the iliac crest around the abdomen and was
recorded to the nearest 0.1 cm. A non-elastic flexible tape was used, with the subjects being
kept in a standing position with minimal respiration and no clothing covering the waist area
or compressions on the skin. The waist-to-height ratio was calculated as well. Pubertal stages
were determined by physical examination, using the criteria of Marshall and Tanner. Systolic
BP (SBP) and diastolic BP (DBP) were measured three times at 2-minute intervals using a mer-
cury sphygmomanometer with an appropriate cuff size after participants had been sitting qui-
etly for at least 15 minutes, with their right arm being supported at the level of the heart, and
feet resting flat on the floor, prior to other physical evaluations and at least 30 minutes after
blood sampling. Mean values were used for all these analyses. Hypertension was determined
only if BP values recorded at enrollment and testing day were both found elevated. After a
12-hour overnight fast, blood samples were taken for measurement of: glucose (mg/dL), insu-
lin (μUI/mL), total cholesterol (mg/dL), high density lipoprotein (HDL)-cholesterol (mg/dL),
triglycerides (mg/dL), aspartate aminotransferase (AST, IU/L), alanine aminotransferase
(ALT, IU/L), uric acid (mg/dL), creatinine (mg/dL), IGF1 (ng/mL), 25-hydroxy (OH) vitamin
D (ng/mL), using standardized methods in the Hospital’s Laboratory [9]. Low-density lipopro-
tein (LDL)-cholesterol was calculated by the Friedwald formula. AST-to-ALT ratio was calcu-
lated. Uric acid (mg/dL) was measured by the Fossati method using uricase with a Trinder-like
endpoint. Serum creatinine concentration (mg/dL) was measured by the enzymatic method.
Glucose was determined by the hexokinase method (Slein Method, Advia 1200/1800/2400
Autoanalyzer; Bayer Diagnostics, Leverkusen, Germany) with an intra-assay coefficient of
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variation of 0.7–2.3% (range 0.0 mg/dL -700.0 mg/dL). Insulin was determined by an immuno-
assay method (Advia Centaur1; Bayer Diagnostics, Leverkusen, Germany) with an intra- and
inter-assay coefficient of variation of 3.2–4.6% and 2.6–5.9%, respectively (range 0.5 mU/L-
300.0 mU/L). Urine albumin (mg/L) was determined by an advanced immunoturbidimetric
assay, and urine creatinine (mg/dL) was measured using the enzymatic method.
Subjects also underwent OGTT (1.75 g of glucose solution per kg, maximum 75 g), and
samples were drawn for the determination of glucose and insulin every 30 minutes. The area
under the curve (AUC) was calculated according to the trapezoidal rule. Insulin resistance was
calculated using the formula for homeostasis model assessment (HOMA)-IR. Insulin sensitiv-
ity at fasting and during OGTT was calculated with the formula of the Quantitative Insulin-
Sensitivity Check Index (QUICKI) and Matsuda index (ISI). Insulinogenic (InsI) and disposi-
tion (DI) indexes were also calculated as previously reported [10]. The stimulus for insulin
secretion in the increment in plasma glucose as the insulinogenic index was calculated as the
ratio of the changes in insulin and glucose concentration from 0 to 30 minutes (InsI). Βeta-cell
compensatory capacity was evaluated by the disposition index defined as the product of the ISI
and InsI (DI) [11]. Glucose was expressed in mg/dL (1 mg/dL = 0.05551 mmol/L) and insulin
in μUI/mL (1 μUI/mL = 7.175 pmol/L) in each formula.
Definitions
Subjects were classified as overweight or obese according to age- and sex-specific IOTF cut-
offs [7]. WC percentiles were stratified according to sex and age, identifying abdominal obesity
as the presence of WC 90th percentile or a waist-to-height ratio of 0.5 [10]. SBP and DBP val-
ues were evaluated according to percentiles for age, sex and height, and arterial hypertension
was defined as SBP or DBP> 95th percentile. Triglycerides, LDL- and HDL-cholesterol per-
centiles for age and sex were classified according to the Lipid Research Clinic Pediatric Preva-
lence Study. Dyslipidemia was defined as the presence of triglycerides 90th percentile, HDL-
cholesterol 10th percentile or LDL 90th percentile. Impaired fasting glucose and impaired
glucose tolerance were defined as fasting plasma glucose 100–125 mg/dL (5.6 to 6.9 mmol/
L) and 2-hour post-OGTT, glucose 140–199 mg/dL (7.8 to 11.0 mmol/L), respectively. Uric
acid 5.5 mg/dL was considered abnormal [12]. According to the NKF-K/DOQI Guidelines
for chronic kidney disease (CKD) in children and adolescents [13], the eGFR was calculated
using the modified Schwartz’s formula [14]: eGFR (mL/min/1.73 m2) = [0.413 x patient’s height
(cm)] / serum creatinine (mg/dL). The normal renal function of patients [mean eGFR ± stan-
dard deviation (SD) in mL/min/1.73 m2] was calculated based on age and gender according to
NKF-K/DOQI Guidelines [13]. 2–12 year-old males and females: 133±27 mL/min/1.73 m2; 13–
21 year-old males: 140±30 mL/min/1.73m2; and 13–21 year-old females: 126±22 mL/min/1.73
m2. Because only 6 subjects had eGFR lower or higher than ±2SD, the population was divided
into four categories according to age and gender ±1SD (range:< -1 SD; -1-0 SD; 0–1 SD;> 1
SD). All subjects collected first-morning urine samples at rest. Urine albumin-to creatinine-
ratio (u-ACR; mg/g) was calculated as follows: [urine albumin (mg/dL)/urine creatinine (g/
dL)]. Microalbuminuria was defined as u-ACR ranging from 30 to 300 mg/g [15]. We collected
two more samples from the subjects found positive for microalbuminuria to confirm the mea-
surement. Microalbuminuria was diagnosed if all the three samples were found positive.
Statistical analysis
All data are expressed as mean ± SD, absolute values or percentages. In the case of microalbu-
minuria, the u-ACR mean values of the three first-morning samples were used as continuous
variables. With an expected prevalence of 14% of microalbuminuria [6], a confidence level of
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99.0% and a margin of error of 5.0%, a population size of 320 individuals was estimated suffi-
cient to reflect our target population. Skewed variables were logarithmically transformed.
ANOVA was used to determine the differences among sex, the presence of microalbuminuria,
hyperuricemia, and the eGFR subgroups with a Bonferroni post-hoc test for multiple compari-
sons in the latter. Analysis of covariance (ANCOVA) was also used for hyperuricemia and
eGFR and covariates were age, sex, puberty and BMI (Model 1) or WC (Model 2), according
to the significant relationship with dependent variables. Logistic regression was used to deter-
mine the association of microalbuminuria, eGFR and uric acid with the odds ratio (OR, 95%
CI) of each cardiometabolic risk factor. Covariates of model 1 and 2 were also used in logistic
regression for hyperuricemia and eGFR. Correlations as well as partial correlations were per-
formed. Significance was assumed at p< 0.05. The analysis was carried out with SPSS for Win-
dows version 17.0 (SPSS Inc., Chicago, IL, USA). The database of the study is available upon
request for validation or collaboration purposes as it includes other data (e.g. family history
and other biochemical variables) not yet analyzed.
Results
Anthropometric and metabolic characteristics of patients
Nineteen out of 379 subjects selected were excluded because they did not satisfy inclusion cri-
teria (fifteen subjects did not have adequate blood sampling, and 4 were without at least 3
urine collections). The final dataset included 360 participants (180 males and 180 females),
aged 3 to 18 years, with a mean age of 10.9±3.0 years. Of the 360 participants, 18 subjects did
not undergo OGTT (fifteen refused, 3 had analyses missing for technical problems), but had a
complete fasting biochemical evaluation. Among patients 88% of them were obese, and 12%
overweight. Almost all subjects had a WC 90th percentile (97.8%) with an overall mean of
the waist-to-height ratio of 0.63±0.11, without differences between sexes. The clinical and bio-
chemical characteristics of subjects are reported in Table 1. Hypertension was diagnosed in
216 (60.0%) subjects. Eighty-eight subjects (24.4%) had triglycerides 90th percentile; 148
(41.1%) had HDL-cholesterol 10th percentile; and 29 (8.0%) had LDL-cholesterol 90th
percentile. Twenty subjects (5.5%) had impaired fasting glucose, 19 (5.2%) impaired glucose
tolerance and 4 (1.1%) both metabolic dysfunctions. One patient had type 2 diabetes.
Microalbuminuria and associations between eGFR, uric acid, and other
cardiometabolic variables
Microalbuminuria was detected in 6.4% (23/360) of subjects. In patients with or without
microalbuminuria, uric acid was 5.5 mg/dL in 34.7% (8/23) and 27.0% (91/337) of them,
respectively (p = 0.278). All patients with microalbuminuria had eGFR> 0 SD. In particular,
69.6% (16/23) of them had eGFR > 1 SD. In the entire cohort without microalbuminuria,
91.7% (309/337) had eGFR > 0 SD, and in 60.2% (203/337) of them the eGFR was > 1SD.
Subjects with microalbuminuria had lower insulin levels at 30-minute post-OGTT (81.8±
72.8 mUI/L vs 122.3±163.5; p< 0.02) and lower insulinogenic index (InsI) (0.74±5.08 vs 2.24±
4.04; p< 0.05) than those without it. No correlations between u-ACR as a continuous variable
and cardiometabolic alterations were found.
eGFR evaluation and its association with microalbuminuria, uric acid, and
other cardiometabolic variables
In 1.4% (5/360) of patients, eGFR was < -1 SD, while in 4 of them it was < -2 SD. Further-
more, eGFR was > 1SD in 60.8% (219/360) of subjects, with 2 of them displaying an eGFR > 2
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Table 1. Clinical and biochemical features of the study population according to sex.
Overall M F
Subjects 360 180 180
Age (years) 10.9±3.0 10.7±2.8 11.1±3.3
Puberty PP 155 (43.1%) 98 (54.4%) 57 (31.7%) †
P 205 (56.9%) 82 (45.6%) 123 (68.3%) †
BMI (kg/m2) 28.12±4.52 27.83±3.85 28.40±5.09
Obesity IOTF 317 (88.0%) 159 (88.3%) 158 (87.8%)
BMI SDS (kg/m2) 2.09±0.46 2.06±0.41 2.13±0.50
Waist circumference (cm) 90.8±13.4 90.6±12.0 91.1±14.6
Waist/Height ratio 0.63±0.11 0.62±0.10 0.64±0.11
SBP (mmHg) 126±16.1 126±16.8 126±15.3
SBP percentile 90±14.9 89±15.3 90±14.5
DBP (mmHg) 79±10.8 79±10.8 79±10.7
DBP percentile 87±15.3 87±15.1 87±15.3
Total cholesterol (mg/dL) 145.6±27.7 144.6±26.9 146.8±28.5
HDL-c (mg/dL) 42.8±8.7 43.1±8.6 42.5±8.7
LDL-c (mg/dL) 87.3±23.5 86.9±23.4 87.7±23.7
Triglycerides (mg/dL) 77.8±43.5 72.4±35.8 83.1±9.6

AST (IU/L) 23.8±7.0 25.2±7.0 22.5±6.8 †
ALT (IU/L) 24.3±13.0 26.4±15.8 22.2±8.9

AST/ALT ratio 1.10±0.39 1.11±0.38 1.10±0.39
Uric acid (mg/dL) 4.87±1.20 4.97±1.30 4.76±1.07
IGF-1 (ng/mL) 286.0±129.7 259.2±129.7 313.1±124.2 †
eGFR (mL/min/1.73m2) 119.78±19.70 120.6±19.4 118.91±19.95
GlcT0’ (mg/dL) 87.9±7.3 88.3±7.1 87.5±7.5
GlcT30’ (mg/dL) 134.8±22.4 136.9±23.0 132.7±22.5

GlcT60’ (mg/dL) 115.1±25.9 116.1±26.5 114.0±25.3
GlcT90’ (mg/dL) 108.9±20.0 108.7±19.5 107.5±21.3
GlcT120’ (mg/dL) 108.0±21.6 109.9±18.3 106.0±18.3

AUC Glc (mg/dLh/dL) 13816.4±2866.7 14035.7±3513.6 13587.8±1965.3
Mean Glc (mg/dL) 111.7±20.5 113.4±24.6 109.9±14.9
InsT0’ (mUI/L) 16.4±11.4 14.7±10.0 18.1±12.4

Mean Ins (mUI/L) 75.6±62.3 72.9±67.5 78.3±56.6
HOMA-IR 3.66±2.80 3.37±2.72 3.96±2.85

ISI 4.71±4.70 4.77±3.78 4.66±5.50

QUICKI 0.33±0.05 0.33±0.04 0.33±0.05

InsI 2.14±4.04 2.05±4.88 2.22±2.96
DI 6.79±16.84 6.38±11.96 7.22±20.73
u-ACR (mg/g) 11.30±26.99 9.11±20.64 13.48±32.01

Data are expressed as mean±SD. p value < 0.01; < 0.0001†. OGTT data are available for 342 or 345 subjects.
Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; AUC: area under the curve; BMI:
body mass index; DI: disposition index; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; F:
female; GlcT0’: fasting glucose; GlcT30’,T60’,T90’,T120’: post-challenge glucose; HDL-c: high density lipoprotein
cholesterol; HOMA-IR: homeostatic model assessment of insulin resistance; InsI: insulinogenic index; InsT0’: fasting
insulin; IOTF: International Obesity Task Force; ISI: insulin sensitivity index; LDL-c: low density lipoprotein
cholesterol; M: male; P: pubertal; PP: prepubertal; QUICKI: quantitative insulin-sensitivity check index; SBP: systolic
blood pressure; u-ACR: urinary albumin-to-creatinine ratio.
https://doi.org/10.1371/journal.pone.0193755.t001
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SD. Anthropometric and metabolic characteristics of subjects according to eGFR categories
are reported in Table 2. Compared with subjects with eGFR < -1 SD, patients with eGFR> 1
SD showed higher SBP, AST, ALT, glucose and insulin during OGTT, insulin resistance
(Fig 1, Panel A and B); they also had lower sensitivity indexes after both crude analysis and
ANCOVA (Fig 1, Panel C and D).
Subjects with an eGFR within 0 and 1 SD had higher odds to have triglycerides < 90th per-
centile in both crude and controlled models (model 2; OR 1.750; CI 1.002–3.056; p< 0.04).
eGFR was correlated with many variables in the crude model. After adjusting for age, sex,
puberty, and BMI, eGFR was positively associated with WC, fasting insulin, glucose levels at
90 and 120 minutes, AUC and mean glucose, insulin at 120 minutes, mean insulin and u-
ACR, and negatively associated with DPB, uric acid, ISI, and QUICKI. After adjusting for age,
sex, puberty, and WC, eGFR was positively associated with fasting insulin, glucose levels at 90
and 120 minutes, AUC and mean glucose, HOMA-IR and u-ACR, and negatively associated
with DPB, uric acid, ISI, and QUICKI (Table 3).
Hyperuricemia evaluation and its association with microalbuminuria,
eGFR and other cardiometabolic variables
Hyperuricemia was present in 27.5% (99/360) of subjects, of whom 8.1% (8/99) had microal-
buminuria, whereas microalbuminuria was found in 5.7% (15/261) of subjects without hyper-
uricemia. Interestingly, 64.6% (64/99) of subjects with hyperuricemia had eGFR > 1 SD, and
26.3% (26/99) were between 0 and 1 SD. In contrast, no subject with eGFR < -1 SD had hyper-
uricemia. Conversely, 59.4% (155/261) of subjects without hyperuricemia had eGFR> 1 SD,
and 33.3% (87/261) were between 0 and 1 SD.
Subjects with hyperuricemia were older, had higher BMI, BMI SDS, waist circumference,
SBP, DBP, triglycerides, ALT and IGF-1 levels and lower HDL-cholesterol, AST, AST to ALT
ratio, eGFR and u-ACR compared with those with normal acid uric levels. Moreover, subjects
with hyperuricemia showed higher glucose and insulin, either at fasting or as responses to
OGTT, associated with higher insulin resistance and lower insulin sensitivity than those with-
out hyperuricemia. After controlling for confounding factors, subjects with hyperuricemia
maintained higher levels of IGF-1 and lower eGFR compared to those with normal acid uric
levels (Table 4). Uric acid levels were positively associated with ALT, IGF-1, HOMA-IR, fasting
insulin, glucose levels at 60, 90 and 120 minutes, AUC and mean glucose, insulin at 60 min-
utes, and negatively associated with HDL-cholesterol, AST to ALT ratio, eGFR, and QUICKI,
also when corrected for covariates (Table 5).
Lastly, hyperuricemia was associated with hypertension (OR: 2.086, CI 1.257–3.460,
p< 0.003), HDL-cholesterol 10th percentile (OR: 2.001, CI 1.252–3.198; p< 0.003) and
glucose 155.0 mg/dL at 60 minutes after OGTT (OR: 2.350, CI 1.045–5.282; p< 0.03) in
both crude and controlled models.
Discussion
This study shows a worsened metabolic profile in obese children with normal eGFR higher
than 1 SD or with abnormally high serum uric acid levels. In particular, post-OGTT glucose
levels were found to be higher, albeit within standard cutoffs, in those individuals with
eGFR> 1 SD. Furthermore, subjects with microalbuminuria did not display a major
impairment in their cardiometabolic alterations, although all of them had eGFR> 0 SD.
In recent years, a positive correlation between microalbuminuria and obesity in adult
patients has been clearly established [3]. However, in pediatric patients such correlation
appears to be less obvious and only partially understood probably due to the lack of consistent
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Table 2. Anthropometric and metabolic characteristics of the study population according to eGFR stratified for percentiles, age and sex dependent, based on
NKF-K/DOQI Guidelines.
Categories of eGFR P value
< - 1 SD - 1–0 SD 0–1 SD > 1 SD
Subjects 5 (1.4%) 23 (6.4%) 113 (31.4%) 219 (60.8%)
Age (years) 11.1±4.0 11.7±3.0 10.7±3.1 10.9±2.9 ns
Sex M 3 (60%) 5 (21.7%)  44 (38.9%) ‡‡ 128 (58.5%) < 0.0001
F 2 (40%) 18 (78.3%)  69 (61.1%) ‡‡ 91 (41.5%)
Puberty PP 2 (40%) 5 (21.7%) 57 (50.4%) 91 (41.5%) ns
P 3 (60%) 18 (78.3%) 56 (49.6%) 128 (58.5%)
BMI (kg/m2) 30.13±6.74 29.50±5.43 27.50±4.98 28.25±4.06 ns
BMI SDS (kg/m2) 2.35±0.63 2.21±0.55 2.03±0.48 2.11±0.43 ns
Waist circumference (cm) 97.1±20.3 93.8±14.1 § 87.5±13.0 ‡‡ 92.1±13.0 < 0.009
Waist/Height ratio 0.64±0.08 0.63±0.09 0.61±0.08 0.641±0.11 ns
SBP (mmHg) 135±10 128±15.5 123±16.0 ‡‡ 128±16.2 < 0.02
SBP percentile 98±1.3 92±9.23 86±17.5 ‡‡ 91±13.7 < 0.01
DBP (mmHg) 86±4.1 83±10.9 79±11.1 79±10.6 ns
DBP percentile 98±1.9 92±8.3 87±14.5 86±16.1 ns
Total cholesterol (mg/dL) 141.8±21.3 138.9±27.5 141.6±25.6 148.5±28.6 ns
HDL-c (mg/dL) 38.8±8.9 42.3±9.2 43.5±9.4 42.6±8.2 ns
LDL-c (mg/dL) 86.4±12.5 83.9±26.9 83.4±22.7 89.7±23.6 ns
Triglycerides (mg/dL) 83.6±54.3 70.5±22.6 74.6±39.6 80.0±46.8 ns
AST (IU/L) 23.6±10.7 19.5±6.0 §,  22.9±5.9 †† 24.8±7.4 < 0.002
ALT (IU/L) 31.8±25.3 23.7±10.2 20.8±8.3 ‡‡ 25.9±14.5 < 0.001
AST/ALT ratio 0.86±0.29 ‡ 0.89±0.31 ¶ 1.20±0.37 ‡‡ 1.08±0.39 < 0.001
Uric acid (mg/dL) 4.70±0.43 5.30±0.89 4.72±1.16 4.90±1.24 ns
IGF-1 (ng/mL) 255.5±102.6 324.4±113.7 280.8±133.1 286.6±130.3 ns
GlcT0’ (mg/dL) 86.6±4.9 87.04±5.75 86.9±7.2 88.5±7.5 ns
GlcT30’ (mg/dL) 152.5±28.0 † 123.5±18.5 §, # 134.2±23.7 135.8±22.3 < 0.0001
GlcT60’ (mg/dL) 122.2±36.4 106.7±19.5 111.0±27.2 117.6±25.3 ns
GlcT90’ (mg/dL) 121.0±24.7 † 96.0±16.4  104.1±19.17 ‡‡ 110.8±20.6 < 0.001
GlcT120’ (mg/dL) 115.6±21.1 100.0±13.6  104.4±17.4 ‡‡ 110.3±20.6 < 0.009
AUC Glc (mg/dLh/dL) 22287.0±17283. 9 † 12614.2±1278.7  13393.9.±2008.8 †† 13930.7.±1868.0 < 0.004
Mean Glc (mg/dL) 168.8±117.3  102.9±9.5  108.5±15.0 †† 112.6±14.3 < 0.005
InsT0’ (mUI/L) 21.7±8.8 13.7±7.1 13.7±9.7 ‡‡ 17.9±12.3 < 0.006
Mean Ins (mUI/L) 106.0±39.8 60.2±29.7 65.8±47.5 80.9±69.9 ns
HOMA-IR 4.62±1.92 2.97±1.50 2.95±2.13 ‡‡ 4.08±3.12 < 0.02
ISI 2.18±1.01 4.24±1.16 6.05±6.85 ‡‡ 4.18±3.40 < 0.005
QUICKI 0.31±0.01 0.33±0.02 0.35±0.05 §§ 0.32±0.04 < 0.001
InsI 2.14±1.27 2.81±3.75 2.20±1.91 2.04±4.79 ns
DI 5.56±4.48 9.09±9.04 10.30±13.70 ‡‡ 4.92±18.61 < 0.05
u-ACR (mg/g) 7.35±3.81 4.83±5.18 9.91±18.83 12.78±31.72 ns
Data are expressed as mean±SD. p value -1SD vs -1-0 SD: <0.05; < 0.01†. -1SD vs 0-1SD: < 0.05‡. -1-0 SD vs 0–1 SD: < 0. 05§; < 0.0001¶; -1-0 SD vs> 1SD: < 0.05#; <
0.01. 0–1 SD vs> 1SD: < 0.05††; < 0.01‡‡; < 0.0001§§. ns: not significant. ANOVA analysis with a Bonferroni post-hoc test was used. OGTT data are available for 342
or 345 subjects. Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; AUC: area under the curve; BMI: body mass index; DI: disposition
index; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; F: female; GlcT0’: fasting glucose; GlcT30’,T60’,T90’,T120’: post-challenge glucose;
HDL-c: high density lipoprotein cholesterol; HOMA-IR: homeostatic model assessment of insulin resistance; InsI: insulinogenic index; InsT0’: fasting insulin; IOTF:
International Obesity Task Force; ISI: insulin sensitivity index; LDL-c: low density lipoprotein cholesterol; M: male; P: pubertal; PP: prepubertal; QUICKI: quantitative
insulin-sensitivity check index; SBP: systolic blood pressure; u-ACR: urinary albumin-to-creatinine ratio.
https://doi.org/10.1371/journal.pone.0193755.t002
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data on large-sized cohorts. In this regard, here we show a prevalence of 6.4% of microalbumi-
nuria in a large cohort of obese children and adolescents, which is in good agreement with pre-
vious data reporting prevalence of microalbuminuria ranging between 0.3% and 10.1% in
similar patient groups [16–21]. These studies, including ours, however appears to underesti-
mate the prevalence of microalbuminuria when compared to other reports showing a much
higher prevalence of microalbuminuria in obese children, which could go as high as 37.0%
[22, 23]. This discrepancy could be explained by different modalities of urine sample collection
Fig 1. Relationship between glucometabolic parameters and stratified estimated glomerular filtration rate (eGFR) levels. (Panel A) Plasma glucose
levels (mg/dL) after 2-hour post-glucose tolerance test (OGTT) (T120’); (Panel B) homeostatic model assessment of insulin resistance (HOMA-IR); (Panel
C) insulin sensitivity index (ISI); (Panel D) disposition index (DI); p value< 0.05;< 0.01 after ANOVA corrected for confounding factors (i.e. sex,
puberty, BMI).
https://doi.org/10.1371/journal.pone.0193755.g001
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[22] or by the measurement of urinary albumin excretion rate per minute time rather than u-
ACR [23]. Moreover, other variables such as postural changes and exercise before the testing
session, as well as ethnicity, might account for data variability [24], even though no evidence
indicating that this is indeed the case in obese children has been found in previous studies
[18, 19].
Associations between microalbuminuria and other cardiometabolic markers in obese chil-
dren and adolescents have been reported in some [16, 18, 20, 21, 22, 25] but not all studies [17,
19, 26], including ours. Although this lack of correlation could be explained by the young
Table 3. Partial correlations between eGFR and microalbuminuria, uric acid and other cardiometabolic variables.
eGFR Model 1 Model 2
r P value r P value
Age (years)
BMI (kg/m2) -0.062 ns
BMI SDS (kg/m2)
Waist circumference (cm) 0.150 < 0.005
Waist/Height ratio
SBP (mmHg) 0.034 Ns 0.016 ns
DBP (mmHg) - 0.122 < 0.002 -0.131 < 0.01
Total cholesterol (mg/dL) 0.092 Ns 0.084 ns
HDL-c (mg/dL) 0.065 Ns 0.071 ns
LDL-c (mg/dL) 0.067 Ns 0.066 ns
Triglycerides (mg/dL) 0.026 Ns -0.002 ns
AST (IU/L) 0.094 Ns 0.085 ns
ALT (IU/L) 0.037 Ns 0.012 ns
AST/ALT ratio -0.11 Ns -0.004 ns
Uric acid (mg/dL) -0.172 < 0.0001 -0.217 < 0.0001
IGF-1 (ng/mL) 0.021 Ns 0.042 ns
GlcT0’ (mg/dL) 0.078 Ns 0.090 ns
GlcT30’ (mg/dL) 0.032 Ns 0.039 ns
GlcT60’ (mg/dL) 0.077 Ns 0.083 ns
GlcT90’ (mg/dL) 0.174 < 0.001 0.176 < 0.001
GlcT120’ (mg/dL) 0.164 < 0.002 0.168 < 0.002
AUC Glc (mg/dLh/dL) 0.132 < 0.01 0.128 < 0.001
Mean Glc (mg/dL) 0.131 < 0.01 0.140 < 0.01
Mean Ins (mUI/L) 0.109 < 0.04 0.080 ns
HOMA-IR 0.164 < 0.02 0.141 < 0.009
ISI -0.131 < 0.01 -0.108 < 0.05
QUICKI -0.176 < 0.01 -0.140 < 0.009
InsI 0.009 Ns 0.002 ns
DI -0.047 Ns -0.041 ns
u-ACR (mg/g) 0.124 < 0.02 0.128 < 0.01
Model 1: controlled for sex, age, puberty and BMI. Model 2: controlled for sex, age, puberty and waist circumference. ns: not significant. OGTT data are available for 342
or 345 subjects. Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; AUC: area under the curve; BMI: body mass index; DI: disposition
index; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; GlcT0’: fasting glucose; GlcT30’,T60’,T90’,T120’: post-challenge glucose; HDL-c: high
density lipoprotein cholesterol; HOMA-IR: homeostatic model assessment of insulin resistance; InsI: insulinogenic index; InsT0’: fasting insulin; ISI: insulin sensitivity
index; LDL-c: low density lipoprotein cholesterol; QUICKI: quantitative insulin-sensitivity check index; SBP: systolic blood pressure; u-ACR: urinary albumin-to-
creatinine ratio.
https://doi.org/10.1371/journal.pone.0193755.t003
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Table 4. Anthropometric and metabolic characteristics of the study population according to uric acid.
URIC ACID P value
Normal High Model 1 Model 2
Age (years) 10.2±3.0 12.7±2.5
BMI (kg/m2) 27.1±4.5 30.8±4.7 ns
BMI SDS (kg/m2) 2.03±0.46 2.27±0.54 ns
Waist circumference (cm) 87.5±13.4 100.3±12.4 < 0.0001
Waist/Height ratio 0.62±0.10 0.64±0.12 ns
SBP (mmHg) 123.2±16.1 134.5±17.7 < 0.01 ns
SBP percentile 88.7±15.0 92.1±13.7 < 0.01 ns
DBP (mmHg) 77.8±10.7 84.2±10.8 < 0.05 ns
DBP percentile 85.6±16.2 90.2±12.4 < 0.05 ns
Total cholesterol (mg/dL) 146.9±28.1 142.1±26.4 ns ns
HDL-c (mg/dL) 43.8±8.7 40.1±7.9 ns ns
LDL-c (mg/dL) 88.2±23.8 84.8±22.8 ns ns
Triglycerides (mg/dL) 74.6±43.5 86.1±49.7 ns ns
AST (IU/L) 24.2±7.0 22.9±6.6 ns ns
ALT (IU/L) 23.1±13.1 27.5±16.6 ns ns
AST/ALT ratio 1.16±0.39 0.95±0.30 ns ns
Uric acid (mg/dL) 4.3±0.8 6.3±0.7 ns ns
IGF-1 (ng/mL) 258.6±115.5 353.8±132.4 < 0.04 < 0.03
eGFR (mL/min/1.73m2) 121.8±19.4 113.6±18.5 ns < 0.001
25-OH VitD (ng/mL) 20.3±9.2 20.3±9.6 ns ns
GlcT0’ (mg/dL) 87.3±8.9 90.4±12.3 ns ns
GlcT30’ (mg/dL) 135.3±23.5 133.2±20.6 ns ns
GlcT60’ (mg/dL) 111.7±25.8 123.2±26.4 ns ns
GlcT90’ (mg/dL) 106.4±20.7 112.6±22.0 ns ns
GlcT120’ (mg/dL) 106.6±18.7 111.8±19.7 ns ns
AUC Glc (mg/dLh/dL) 1370.2±2870.7 14109.1±1943.1 ns ns
Mean Glc (mg/dL) 110.7±20.6 114.3±14.9 ns ns
InsT0’ (mUI/L) 146.1±13.1 22.3±18.9 < 0.01 ns
InsT30’ (mUI/L) 123.6±186.2 108.4±80.8 ns ns
InsT60’ (mUI/L) 80.0±86.7 109.7±104.8 ns ns
InsT90’ (mUI/L) 68.9±65.2 86.6±75.2 ns ns
InsT120’ (mUI/L) 71.2±92.7 100.5±126.3 ns ns
AUC Ins (mUIh/dL) 9508.7±8260.3 10988.4±7915.6 ns ns
Mean Ins (mUI/L) 72.9±62.6 85.6±64.2 ns ns
HOMA-IR 3.27±4.25 5.33±6.84 < 0.05 ns
ISI 5.13±4.79 3.66±2.91 ns ns
QUICKI 0.34±0.04 0.32±0.05 ns ns
InsI 2.17±4.50 2.06 ±2.50 ns ns
DI 7.25±6.84 5.62±6.18 ns ns
u-ACR (mg/g) 11.59±26.93 10.53±24.50 ns ns
Data are expressed as mean±SD. ANCOVA Model 1: controlled for sex, age, puberty and BMI. ANCOVA Model 2: controlled for sex, age, puberty and waist
circumference. ns: not significant. OGTT data are available for 342 or 345 subjects. Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase;
AUC: area under the curve; BMI: body mass index; DI: disposition index; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; F: female; GlcT0’:
fasting glucose; GlcT30’,T60’,T90’,T120’: post-challenge glucose; HDL-c: high density lipoprotein cholesterol; HOMA-IR: homeostatic model assessment of insulin
resistance; InsI: insulinogenic index; InsT0’: fasting insulin; InsT30’,T60’,T90’,T120’: post-challenge glucose; ISI: insulin sensitivity index; LDL-c: low density lipoprotein
cholesterol; M: male; QUICKI: quantitative insulin-sensitivity check index; SBP: systolic blood pressure; u-ACR: urinary albumin-to-creatinine ratio; uric acid: high
( 5.5 mg/dL); 25OH VitD: 25-0H vitamin D.
https://doi.org/10.1371/journal.pone.0193755.t004
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mean age of our patients or the low prevalence of microalbuminuria registered in these latter,
our findings do not support a routine assessment of microalbuminuria in all obese children
and adolescents.
Interestingly, we find a lower insulinogenic index in subjects with microalbuminuria,
which is in good agreement with a recent study demonstrating a positive correlation between
microalbuminuria and HbA1c in obese Korean adolescents [21]. In this regard, it has been
hypothesized that the prevalence of microalbuminuria progressively increased as plasma glu-
cose values climbed through the ‘normal range’ into the impaired range of glucose tolerance,
Table 5. Partial correlations between uric acid and microalbuminuria, eGFR and other cardiometabolic variables.
URIC ACID Model 1 Model 2
r P value r P value
Age (years)
BMI (kg/m2) 0.015 ns
BMI SDS (kg/m2)
Waist circumference (cm) 0.169 < 0.002
Waist/Height ratio
SBP (mmHg) 0.105 < 0.05 0.078 ns
DBP (mmHg) 0.076 ns 0.088 ns
Total cholesterol (mg/dL) 0.052 ns 0.044 ns
HDL-c (mg/dL) -0.153 < 0.004 -0.150 < 0.005
LDL-c (mg/dL) 0.081 ns 0.079 ns
Triglycerides (mg/dL) 0.105 < 0.04 0.087 ns
AST (IU/L) 0.018 ns 0.009 ns
ALT (IU/L) 0.115 < 0.03 0.104 < 0.05
AST/ALT ratio -0.118 < 0.02 -0.122 < 0.02
IGF-1 (ng/mL) 0.187 < 0.0001 0.217 < 0.0001
eGFR (mL/min/1.73m2) -0.172 < 0.001 -0.217 < 0.0001
GlcT0’ (mg/dL) 0.070 ns 0.074 ns
GlcT30’ (mg/dL) 0.096 ns 0.089 ns
GlcT60’ (mg/dL) 0.209 < 0.0001 0.206 < 0.0001
GlcT90’ (mg/dL) 0.118 < 0.03 0.111 < 0.04
GlcT120’ (mg/dL) 0.137 < 0.01 0.136 < 0.01
AUC Glc (mg/dLh/dL) 0.176 < 0.001 0.168 < 0.002
Mean Glc (mg/dL) 0.179 < 0.001 0.178 < 0.001
InsT0’ (mUI/L) 0.181 < 0.001 0.014 < 0.009
Mean Ins (mUI/L) 0.114 < 0.003 0.072 ns
HOMA-IR 0.140 < 0.008 0.117 < 0.03
ISI -0.120 < 0.02 -0.096 ns
QUICKI -0.150 < 0.0001 -0.113 < 0.03
InsI -0.037 ns -0.049 ns
DI -0.090 ns -0.091 ns
u-ACR (mg/g) -0.085 ns -0.080 ns
Model 1: controlled for sex, age, puberty and BMI. Model 2: controlled for sex, age, puberty and waist circumference. ns: not significant. Abbreviations: ALT: alanine
aminotransferase; AST: aspartate aminotransferase; AUC: area under the curve; BMI: body mass index; DI: disposition index; DBP: diastolic blood pressure; eGFR:
estimated glomerular filtration rate; GlcT0’: fasting glucose; GlcT30’,T60’,T90’,T120’: post-challenge glucose; HDL-c: high density lipoprotein cholesterol; HOMA-IR:
homeostatic model assessment of insulin resistance; InsI: insulinogenic index; InsT0’: fasting insulin; ISI: insulin sensitivity index; LDL-c: high density lipoprotein
cholesterol; QUICKI: quantitative insulin-sensitivity check index; SBP: systolic blood pressure; u-ACR: urinary albumin-to-creatinine ratio.
https://doi.org/10.1371/journal.pone.0193755.t005
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suggesting that the effect of glucose may be continuous. Furthermore, frequent daily post-
prandial states of relatively higher glucose levels could increase oxidative stress on the vessels
leading to increased urinary albumin excretion secondary to endothelial dysfunction [16].
Moreover, because HbA1c and insulinogenic-index are both related to insulin-resistance, also
the latter could be a responsible for this alteration. This is in agreement with the evidence that
insulin-resistance contributes to micro and macrovascular disease [1, 16].
Since our results appear to indicate that subjects with eGFR> 0 SD have microalbuminuria
and a suboptimal metabolic phenotype, further longitudinal studies on larger populations are
clearly needed to fully establish whether eGFR could be used as a useful marker to stratify
high-risk obese youths.
According to NKF-K/DOQI guidelines [13], we also report eGFR < -1 SD in 1.4% of our
population, who was free of known CKDs. Based on a normal population distribution, a much
greater percentage would be expected to be below -1 SD and again below normal -2 SD. The
fact that the majority of our subjects were stratified above 0 and, to a greater extent, 1 SD indi-
cates a quite alarming skewed distribution of eGFR in obesity, in agreement with some [27],
but not all authors [20, 28]. In fact, differently by us, the distribution observed in the National
Health and Nutrition Examination Survey (NHANES) resulted toward lower eGFR beyond
what is expected. However, the NHANES cohort included only adolescents aged 12–19 years
of general U.S. population [28], while our population was much younger. These contrasting
findings could be due also to different obesity trajectories or different formulas used to deter-
mine eGFR from serum creatinine concentration (i.e Jaffè technique vs Schwartz’s formula)
[14]. Therefore, previous reports have clearly shown that adulthood obesity is associated with
glomerular hyper-perfusion and hyper-filtration as an early sign of physiologic maladaptation
leading, in part, to afferent arteriolar vasodilatation [1]. Of note, we show that microalbumi-
nuria was present only in subjects with eGFR> 0 SD in good agreement with a previous report
[29]. Thus, our findings, together with the observation that childhood obesity positively cor-
relates with a fast decline of eGFR over time, with a 2- to -3 fold higher risk of developing
ESRD [30], should prompt physicians to evaluate the possibility of renal dysfunction in obese
children.
We also show that subjects with eGFR> 1 SD presented with an increased burden of cardi-
ometabolic alterations as recent studies in adults seem to suggest [2]. In particular, in our
young patients with eGFR> 1 SD, systolic blood pressure, glucose, and insulin levels in
response to OGTT and insulin resistance were higher, whereas insulin sensitivity was lower
compared to other subgroups, suggesting a glucose dysregulation mainly after OGTT. The
same condition was also present in patients with eGFR< -1 SD, suggesting a U-shaped rela-
tionship, even though the low number of subjects in the left part of the curve does not allow us
to draw any firm conclusions about its generalizability. A similar U-shaped effect between
eGFR, blood pressure and microalbuminuria has been recently reported by Di Bonito P. et al.
[29], although these authors could not find a significant relationship between eGFR and the
glyco-insulinemic profile at fasting. This discrepancy might be due to the different eGFR cut-
off in adults used in this study.
Overall, our findings raise the possibility that eGFR> 1 SD may be an early predictor of
dysglycemia and pre-diabetes, a possibility that could be further explored by investigating the
relationships among post-challenge glucose, insulin levels and kidney function in youths. Our
data are also consistent with findings by Matsushita et al., who have recently shown that the
inclusion of eGFR and u-ACR among traditional risk predictors greatly improved the discrim-
ination of cardiometabolic outcomes in adults [4]. However, additional longitudinal studies
are clearly needed to establish the evolution and distribution of eGFR in obese children and
explain its pathophysiological significance over time.
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In our study, we show an inverse correlation between eGFR and uric acid, which is in line
with previous reports on several adult populations [6] and adolescents with type 1 diabetes [31].
While in the past hyperuricemia was thought to result from a decreased uric acid clearance due
to kidney damage, it now seems that uric acid per se might play a role in the natural history of
GFR decline [6]. In this regard, here we show that hyperuricemic patients are at increased risk
of having a 1-hour post-OGTT glycemia 155.0 mg/dL. This cut-off seems to be associated
with an increased metabolic risk in subjects with a post-challenge normal glucose tolerance as
well as with the development of an overt type 2 diabetes rather than fasting glucose [32]. More-
over, serum uric acid levels are closely related to both early-phase insulin secretion and 2-hour
post-challenge glucose levels in adults with apparently normal glucose regulation [33].
To the best of our knowledge, this is the first study in a pediatric obese population where a
positive association between uric acid and glucose response after OGTT has been found. In
line with previous evidence [5], we confirm a worse cardiometabolic profile in subjects with
hyperuricemia, which increased the odds of hypertension and HDL-cholesterol 10th percen-
tile. In agreement with recent studies in adults [34], we also observed an association between
uric acid and ALT, which suggests that uric acid may be an independent risk factor for liver
diseases.
Although serum uric acid seems a good predictor of renal and cardiometabolic diseases, its
normal values in children and adolescents are still undefined. In this regard, we report an age-
dependent effect on serum uric acid levels. Thus, the fixed cut-off is probably improper in the
pediatric population, while a distribution according to age and sex may be more appropriate.
All in all, our results are limited to a Caucasian population. We included only Caucasian
children and adolescents because ethnic influences on microalbuminuria and serum uric acid
have been reported [18, 19, 24, 35]. Therefore, further studies on more heterogeneous popula-
tions are needed.
Our study has some limitations. First of all, the cross-sectional design does not allow us to
conclude that there is a causal relationship between variables; longitudinal studies might clarify
this aspect. Moreover, a normal-weight control group is lacking, because the study was per-
formed in a tertiary referral center. Another limit is that microalbuminuria was measured on
spot morning urine samples; however, spot u-ACR correlates very well with the urine collec-
tion at the 24-hour time point [19]. Furthermore, we failed to observe a normal distribution of
eGFR in obesity, and a very low percentage of subjects could be stratified in the extreme tails
(±2SD). Thus, studies on larger populations are needed to confirm our data and investigate the
metabolic phenotype of those with an eGFR above or below ±2SD.
On the other hand, our study includes a large sample of subjects as well as the availability of
OGTT for the majority of patients. Moreover, microalbuminuria was confirmed on three sam-
ples, and eGFR was stratified according to the pediatric cut-off, unlike most publications on
pediatric obesity.
In conclusion, our study suggests that eGFR may be helpful in clinical practice to identify
an unhealthy metabolic profile in pediatric obesity. Thus, more attention should be paid to
this relatively inexpensive parameter. Therefore, in subjects with an eGFR> 1 SD or hyperuri-
cemia, we encourage to investigate the early-phase insulin secretion and 2-hour post-challenge
glucose levels. Serum uric acid seems to be another useful tool to diagnose subjects at high risk
of metabolic impairment. However, studies based on larger population are needed to establish
normal references values according to age and sex.
Finally, based on our data, we strongly recommend the inclusion of microalbuminuria only
in routine screenings of pediatric obese patients with eGFR greater than 1 SD. Further studies
on large-sized pediatric cohorts are needed to confirm our finding also in obese children with
an eGFR less than -2 SD or greater than 2 SD.
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